|52 Week Rng||-|
|P/E Ratio (TTM)||-|
|P/E Ratio (Fwd)||-|
|Div & Yield||-|
Portfolio consists of 20 biotechnology/pharmaceutical corporations' stocks. Equal weighting | Passive buy and hold strategy, long term.
Alexion pharmaceuticals develops therapies for rare disease patients. With rather high beta of 1.65, ALXN has shown pretty steady stock price development past 5 years. Earnings grew 863,5% over the past year.